



**For immediate release**

## **Biocon takes “Diabetes Awareness” to the masses**

**Bangalore, India, 7th May, 2010** – Diabetes is a global pandemic and with over 50 million diabetics India is considered the diabetes capital of the world. It is estimated that by 2025, one in every 5 diabetics worldwide is likely to be an Indian.

Biocon is a research driven global bio-pharmaceutical enterprise with research efforts focused on a number of debilitating diseases of which diabetes is a key focus. As a result, the organization is deeply committed to tackle this diabetes menace that is affecting all segments of the Indian populace.

Biocon has launched a massive diabetes awareness campaign branded “WINNING WITH DIABETES”. This is a programme that focuses on diabetes control education in partnership with the medical fraternity and follows the mantra of “KNOW DIABETES TO DEFEAT DIABETES”. A path breaking radio campaign across India focusing on diabetes awareness and control measures for the common man recently received encouraging response.

In line with its “WINNING WITH DIABETES” endeavors, Biocon is now taking the diabetes awareness initiative forward through a personal contact campaign at high footfall locations. **The first such activity is happening in Bangalore on May 8<sup>th</sup> 2010, at the Forum Mall, Koramangala. Timings are from 11a.m to 8.00 p.m.** Biocon counters are being set up where visitors can undertake a free diabetes detection exercise involving blood sugar and BMI (Body mass index) check. The objective is to sensitize the masses to the lurking perils of diabetes and the fact that diabetes control is possible if adequate measures are taken for warning signs and early detection. Biocon team members will simultaneously counsel and educate the public on ways and means to lead a healthy lifestyle, maintain a good diet and benefits of regular exercise – the 3 critical lifestyle factors that can make a big difference to diabetes management. Informative handouts on recommended diet and calorie management, along with diabetes control tips will be distributed.

Rakesh Bamzai, President Marketing at Biocon, the driving factor behind the “WINNING WITH DIABETES” initiative, said “Daily Self Monitoring of Blood Glucose (SMBG) is an important



aspect in controlling diabetes. SMBG reduces the risk of diabetes related complications, improves HbA1c levels and allows early identification of hypoglycemia”.

This unique “WINNING WITH DIABETES” initiative by Biocon is fast gaining momentum and the organization plans to reach out to the common man to enhance awareness of SMBG and other diabetes control measures. The end objective is to curb the diabetes menace and ensure that diabetes patients lead a healthy, happy life.

### **About Biocon Limited**

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance.

Visit us at [www.biocon.com](http://www.biocon.com)

### **Media contact:**

Paula Sengupta  
Biocon Limited  
Tel: +91 80 2808 2222  
Fax: +91 80 2852 3423  
Email: [paula.sengupta@biocon.com](mailto:paula.sengupta@biocon.com)

Varija Belliappa  
Biocon Limited  
Tel: +91 80 2808 2223  
Fax: +91 80 2852 3423  
Email: [varija.belliappa@biocon.com](mailto:varija.belliappa@biocon.com)

Seema Rajarathnam  
Rediffusion Y&R PR  
Tel: +91 9945017082  
Email: [seema.rajarathnam@rediffusionyr.com](mailto:seema.rajarathnam@rediffusionyr.com)



**Press Release: 2**

## **KIRAN MAZUMDAR SHAW NAMED ONE OF TIME MAGAZINE'S TIME 100**

### **TIME'S ANNUAL LIST OF THE 100 MOST INFLUENTIAL PEOPLE IN THE WORLD**

**Bangalore, India, April 29, 2010** —TIME named Kiran Mazumdar Shaw to the 2010 TIME 100, the magazine's annual list of the 100 most influential people in the world. The full list and related tributes appear in the May 10 issue of TIME, available on newsstands on Friday, April 30, and now at [www.time.com/tk](http://www.time.com/tk)

The list, now in its seventh year, recognizes the activism, innovation and achievement of the world's most influential individuals. As Managing Editor Rick Stengel has said of the list in the past, "The TIME 100 is not a list of the most powerful people in the world, it's not a list of the smartest people in the world, it's a list of the most influential people in the world. They're scientists, they're thinkers, they're philosophers, they're leaders, they're icons, they're artists, they're visionaries. People who are using their ideas, their visions, their actions to transform the world and have an effect on a multitude of people."

Kiran Mazumdar Shaw said "TIME is an institution and it is a great honour to be a part of such an esteemed list, sharing the platform with luminaries from so many walks of life. It is a wonderful recognition."

Lance Armstrong, champion cyclist and the founder of LiveStrong, had this to say in his tribute to Kiran "When a parent is lost to cancer in the developing world, it means no school for the kids, no more food on the table and a future in which the only certainty is poverty. In 2010 we'll lose 8 million people as this disease quietly becomes the world's leading cause of death. And developing nations will keep getting hit the hardest.

Facing down this challenge is Dr. Kiran Mazumdar-Shaw. At age 25, she created a biotech company in her garage. Never mind that no one in the '70s knew what biotech was, that she is a woman and that backers were hard to come by because of these two points. Today that start-up, Biocon International, is a \$1 billion operation.

Every year, Shaw donates \$2 million to support health insurance coverage for 100,000 Indian villagers. She devoted \$10 million to creating the 1,400-bed Mazumdar-Shaw Cancer Centre in Bangalore, India. When it opens this year, it will treat poor patients for free in the evenings so they can continue to work and care for their families during the day.

Thank you, Dr. Shaw, for treating cancer like the global crisis it has become."

### **About Biocon Limited**

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms Kiran Mazumdar-Shaw,



is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon's value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon's robust product offering includes the world's first recombinant human insulin, INSUGEN® and India's first indigenously produced monoclonal antibody BIOMAb-EGFR(TM). For more information visit us at [www.biocon.com](http://www.biocon.com)

**Media Contacts**

Paula Sengupta

Biocon Limited

Tel: +91 80 2808 2222

Fax: +91 80 2852 3423

Email: [paula.sengupta@biocon.com](mailto:paula.sengupta@biocon.com)

Varija Belliappa

Biocon Limited

Tel: +91 80 2808 2223

Fax: +91 80 2852 3423

Email: [varija.belliappa@biocon.com](mailto:varija.belliappa@biocon.com)

# **BIOCON GROUP**

**FY2010 vs. FY 2009**  
**Q4 FY 2010 vs Q4 FY 2009**

## **FACT SHEET**

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		(Rs. Crores)
<b>Particulars</b>	<b>As at 31-Mar-10</b>	<b>As at 31-Mar-09</b>
<b><u>SOURCES OF FUNDS</u></b>		
Share Capital	100	100
Reserves & Surplus	1,658	1,411
<b>Total Shareholder's Funds</b>	<b>1,758</b>	<b>1,511</b>
<b>Minority interest</b>	34	25
<b>Deferred Tax Liability</b>	51	47
Secured Loans	332	396
Unsecured Loans	182	128
<b>Total Loan Funds</b>	<b>514</b>	<b>524</b>
<b>Total</b>	<b>2,356</b>	<b>2,106</b>
<b><u>APPLICATION OF FUNDS</u></b>		
<b>Fixed Assets (Net)</b>	1,244	1,221
<b>Intangible Assets</b>	170	163
<b>Investments</b>	431	368
Inventories	372	319
Sundry debtors	446	367
Cash and bank balances	140	12
Loans and advances	134	95
<b>Total Current Assets, Loans &amp; Advances</b>	<b>1,092</b>	<b>792</b>
<b>Less: Current liabilities and provisions</b>	580	438
<b>Net Current assets</b>	<b>512</b>	<b>355</b>
<b>Total</b>	<b>2,356</b>	<b>2,106</b>

**BIOCON LIMITED (CONSOLIDATED)**  
**PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	WITH AXICORP	WITH AXICORP	Variance	WITHOUT AXICORP	WITHOUT AXICORP	Variance
	FY 10	FY 09		FY 10	FY 09	
<b><u>INCOME</u></b>						
Biopharmaceuticals	2,087	1,384	51%	1,180	915	29%
Contract research	281	225	25%	281	225	25%
<b>Total Sales</b>	<b>2,368</b>	<b>1,609</b>	<b>47%</b>	<b>1,461</b>	<b>1,139</b>	<b>28%</b>
Other income	37	65	-43%	32	54	-40%
<b>Total Income / Revenues</b>	<b>2,405</b>	<b>1,673</b>	<b>44%</b>	<b>1,493</b>	<b>1,194</b>	<b>25%</b>
<b><u>EXPENDITURE</u></b>						
Material & Power Costs	1,405	908	55%	681	516	32%
Staff costs	229	168	36%	159	129	23%
Research & Development	78	60	31%	78	60	31%
Forex Loss/ (gain)	6	11	-47%	6	11	-47%
Other Expenses	178	139	28%	114	107	7%
<b>Manufacturing, staff &amp; other exps</b>	<b>1,896</b>	<b>1,285</b>	<b>48%</b>	<b>1,038</b>	<b>822</b>	<b>26%</b>
<b>PBDIT /EBIDTA</b>	<b>509</b>	<b>388</b>	<b>31%</b>	<b>455</b>	<b>372</b>	<b>22%</b>
Interest and finance charges	17	18	-5%	15	15	-4%
<b>PBDT</b>	<b>492</b>	<b>370</b>	<b>33%</b>	<b>440</b>	<b>356</b>	<b>24%</b>
Depreciation	140	110	27%	135	108	26%
<b>PBT</b>	<b>352</b>	<b>260</b>	<b>35%</b>	<b>305</b>	<b>248</b>	<b>23%</b>
Taxes	49	12		32	10	
<b>PROFIT FOR THE PERIOD</b>	<b>303</b>	<b>248</b>	<b>22%</b>	<b>273</b>	<b>238</b>	<b>14%</b>
Add/(less): Minority interest / Share of Losses in Associates	(10)	(8)	21%	(3)	(5)	0%
<b>Profit before Exceptional Items</b>	<b>293</b>	<b>240</b>	<b>22%</b>	<b>270</b>	<b>234</b>	<b>15%</b>
<b>Exceptional Item - Net of Tax</b>	<b>0</b>	<b>(147)</b>		<b>0</b>	<b>(147)</b>	
<b>NET PROFIT (PAT)</b>	<b>293</b>	<b>93</b>	<b>215%</b>	<b>270</b>	<b>87</b>	<b>211%</b>
<b>EPS on issued capital Rs. (before exceptional items)</b>	<b>14.7</b>	<b>12.0</b>		<b>13.5</b>	<b>11.7</b>	

Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 51 Crores for FY2010, Rs 12 Crores in FY2009 (both with and without Axicorp);

**BIOCON LIMITED (CONSOLIDATED)**  
**PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	Q4	Q4	Variance	Q4	Q4	Variance
	WITH AXICORP FY 10	WITH AXICORP FY 09		WITHOUT AXICORP FY 10	WITHOUT AXICORP FY 09	
<b>INCOME</b>						
Biopharmaceuticals	583	398	46%	334	224	49%
Contract research	74	68	9%	74	68	9%
<b>Total Sales</b>	<b>657</b>	<b>466</b>	<b>41%</b>	<b>408</b>	<b>292</b>	<b>40%</b>
Other income	9	20	-57%	7	12	-47%
<b>Total Income / Revenues</b>	<b>666</b>	<b>487</b>	<b>37%</b>	<b>415</b>	<b>304</b>	<b>36%</b>
<b>EXPENDITURE</b>						
Material & Power Costs	398	279	42%	202	131	54%
Staff costs	60	45	35%	42	32	33%
Research & Development	19	20	-5%	19	20	-5%
Forex Loss/ (gain)	4	(5)	-187%	4	(5)	-181%
Other Expenses	45	37	21%	20	25	-20%
<b>Manufacturing, staff &amp; other exps</b>	<b>526</b>	<b>376</b>	<b>40%</b>	<b>288</b>	<b>203</b>	<b>42%</b>
<b>PBDIT /EBIDTA</b>	<b>139</b>	<b>110</b>	<b>26%</b>	<b>127</b>	<b>102</b>	<b>25%</b>
Interest and finance charges	3	6	-46%	3	5	-46%
<b>PBDT</b>	<b>136</b>	<b>104</b>	<b>31%</b>	<b>124</b>	<b>96</b>	<b>29%</b>
Depreciation	37	31	20%	35	30	19%
<b>PBT</b>	<b>99</b>	<b>73</b>	<b>35%</b>	<b>89</b>	<b>67</b>	<b>33%</b>
Taxes	14	(2)		9	(2)	-680%
<b>PROFIT FOR THE PERIOD</b>	<b>85</b>	<b>75</b>	<b>13%</b>	<b>80</b>	<b>68</b>	<b>18%</b>
Add/(less): Minority interest / Share of Losses in Associates	(4)	(9)		(3)	(7)	0%
<b>Profit before Exceptional Items</b>	<b>81</b>	<b>66</b>	<b>22%</b>	<b>77</b>	<b>62</b>	<b>25%</b>
<b>Exceptional Item - Net of Tax **</b>	<b>0</b>	<b>(41)</b>		<b>0</b>	<b>(41)</b>	
<b>NET PROFIT (PAT)</b>	<b>81</b>	<b>25</b>	<b>224%</b>	<b>77</b>	<b>20</b>	<b>280%</b>
<b>EPS on issued capital Rs. (before exceptional items)</b>	<b>4.0</b>	<b>3.3</b>		<b>3.9</b>	<b>3.1</b>	

Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 21 Crores in Q4 FY2010, Rs 6 Crores in Q4 FY2009 (both with and without Axicorp);